A Randomised, Open-Label Study to Evaluate the Efficacy and Safety of a Treatment Optimisation With Trizivir During 96 Weeks After a First Antiretroviral Treatment in HIV-1 Infected Subjects
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Lamivudine/zidovudine/abacavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 26 Feb 2008 Status changed from recruiting to completed.
- 28 May 2007 New trial record.